Skip to content

A comparative study of a combined treatment with fractional carbon dioxide, 0.01% Bimatoprost and narrowband ultraviolet B phototherapy versus a combined treatment with fractional carbon dioxide and narrowband ultraviolet B phototherapy in non-segmental vitiligo: A randomized controlled trial

Efficacy of fractional carbon dioxide, 0.01% Bimatoprost and narrowband ultraviolet B phototherapy versus a combined treatment with fractional carbon dioxide and narrowband ultraviolet B phototherapy in non-segmental vitiligo

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20200923001
Enrollment
18
Registered
2020-09-23
Start date
2020-11-22
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sunburn Infection hypertrophic scar or keloid Allergic contact dermatitis Hypertrichosis Vitiligo Bimatoprost Fractional Co2 laser Narrow band ultraviolet B

Interventions

One side of lesion will be treated by topical bimatoprost 0.01% solution apply twice daily (1 drop for each 2 cm2)+ narrow band ultraviolet rays B twice weekly for 3 months + fractional carbon dioxi
Experimental Drug,Experimental Drug
Topical bimatoprost 0.01% solution&#44
Fractional Co2 laser&#44
Narrow band ultraviolet B,Normal saline&#44

Sponsors

Srinakharinwirot university
Lead Sponsor
Srinakharinwirot university
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patient older than 18 years old. 2.Patient with non-segmental vitiligo which bilateral symmetry and there are 2 more lesions. 3.Lesions stable for at least 1 year. 4.There is no serious underlying disease. 5.Patients are willing to participate in research project with sign the inform consent before attend the study and can be responsible to treatment along total course.

Exclusion criteria

Exclusion criteria: 1. The vitiligo was treated by other treatments within 4 weeks prior attend. 2. History of photosensitivity or disease exacerbated by sun light. 3. History of easily to hypertrophic scar occurs. 4. Patients with sensitivity to bimatoprost such as allergy or asthma. 5. Pregnancy or lactation. 6. Deny or withdraw during attending the project.

Design outcomes

Primary

MeasureTime frame
Evaluate total surface area of lesions 4 months (before treatment, 2nd, 4th, 8th, 12th, 16th) The lesions were taken a photo by digital camera and measured by photoshop program (Adobe photoshop)

Secondary

MeasureTime frame
Evaluate melanin average level and melanin variation 4 months (before treatment, 2nd, 4th, 8th, 12th, 16th) The lesions were measured a melanin average level and melanin variation by Antera 3D camera.,Repigmentation of skin lesions 4 months The lesions will be compared with a photo by digital camera at 2nd ,4th, 8th, 12th and 16th week,Assess the pattern of repigmentation 4 months Assess the lesion by digital camera at 12th and 16th week. ,Assess side effects and frequent of treatment 4 months A note book will be provided to patients for recording the side effects of treatment .,Assess recurrent rate of disease 4 months Dermatologist will compare the lesion between end of treatment (week 12) and week 16 of treatment.,Assess satisfied of treatment 4 months visual analogue scale (VAS) will be assessed at 12th and 16th week.

Countries

Thailand

Contacts

Public ContactSilada Kanokrungsee

Department of dermatology, Faculty of medicine, Srinakharinwirot university

silada@g.swu.ac.th081-9099926

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026